{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:01:32Z","timestamp":1705582892739},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Biopharmaceuticals have recently emerged as effective treatments for refractory pediatric autoimmune conditions. Several reports have shown a relationship between drug concentration, antidrug antibodies, and clinical response in these patients, strongly suggesting the potential interest, usefulness, and reliability of therapeutic drug monitoring (TDM) in children. This article reviews the current state of research in juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric psoriasis from a TDM point of view. There is a remarkable lack of evidence-based data in pediatric patients, which is reflected throughout the article. Most investigations of TDM are focused on research of tumor necrosis factor alpha antagonists in inflammatory bowel disease, albeit preliminary publications are emerging from pediatric rheumatologists and dermatologists. To date, immunogenicity has been a primary concern, particularly regarding infliximab and adalimumab therapy in children, as it may lead to a loss of therapeutic response. Preliminary investigations show that adjusting the dose according to blood drug concentrations improves disease outcomes by overcoming antidrug antibodies, suggesting a crucial role for TDM. Patients who receive other drugs, such as etanercept, abatacept, or tocilizumab, could benefit from TDM because dosage can be optimized by adjusting it to the minimum effective dose.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000423","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T16:58:32Z","timestamp":1496249912000},"page":"370-378","source":"Crossref","is-referenced-by-count":5,"title":["Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics"],"prefix":"10.1097","volume":"39","author":[{"given":"Sara","family":"Murias","sequence":"first","affiliation":[{"name":"Pediatric Rheumatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Magallares","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Albizuri","sequence":"additional","affiliation":[{"name":"Pediatric Dermatology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Pascual-Salcedo","sequence":"additional","affiliation":[{"name":"Immunology, University Hospital La Paz, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, Tours, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"R2-20230814","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.autrev.2012.07.022","article-title":"Systemic juvenile idiopathic arthritis","volume":"12","author":"Martini","year":"2012","journal-title":"Autoimmun Rev."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1542\/peds.2006-0421","article-title":"The American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology. Ophthalmologic examination in children with juvenile rheumatoid arthritis","volume":"117","author":"Cassidy","year":"2006","journal-title":"Pediatrics"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/rheumatology\/kep460","article-title":"BSPAR Standards of care for children and young people with juvenile idiopathic arthritis","volume":"49","author":"Davies","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med."},{"key":"R13-20230814","first-page":"955","article-title":"Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study","volume":"34","author":"Alcobendas","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A double blind, placebo-controlled, multicenter study of the efficacy and safety of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s10067-014-2498-1","article-title":"Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years","volume":"33","author":"Kingsbury","year":"2014","journal-title":"Clin Rheumatol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","article-title":"Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan","volume":"31","author":"Imagawa","year":"2012","journal-title":"Clin Rheumatol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/rheumatology\/keu305","article-title":"Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience","volume":"53","author":"Murias","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response","volume":"44","author":"Skrabl-Baumgartner","year":"2015","journal-title":"Scand J Rheumatol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","article-title":"Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan","volume":"41","author":"Yokota","year":"2014","journal-title":"J Rheumatol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Benedetti","year":"2012","journal-title":"N Engl J Med."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/MIB.0000000000000083","article-title":"Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease","volume":"20","author":"Church","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","article-title":"Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study","volume":"19","author":"Adedokun","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"J Crohns Colitis."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/00365521.2012.741619","article-title":"Serum infliximab concentrations in pediatric inflammatory bowel disease","volume":"48","author":"H\u00e4m\u00e4l\u00e4inen","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/00365521.2015.1027264","article-title":"The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease","volume":"50","author":"Hoekman","year":"2015","journal-title":"Scand J Gastroenterol."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000001029","article-title":"Practical use of infliximab concentration monitoring in pediatric Crohn disease","volume":"62","author":"Minar","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","article-title":"Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD","volume":"21","author":"Zitomersky","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/MIB.0000000000000003","article-title":"A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease","volume":"20","author":"Vahabnezhad","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","article-title":"Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease","volume":"13","author":"Grossi","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure\u2013efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/MIB.0000000000000715","article-title":"Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease","volume":"22","author":"Dubinsky","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: a review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"R53-20230814","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FTD.0000000000000410","article-title":"Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases","volume":"39","author":"Paintaud","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R57-20230814","article-title":"MAGE position statement: therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases: best clinical practice","author":"Dreesen","year":"2017","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:11:49Z","timestamp":1692051109000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000423","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}